DNA Methyltransferase Contributes to Delayed Ischemic Brain Injury

Matthias Endres,1,2 Andreas Meisel,2 Detlev Binszkiewicz,3 Shobu Namura,1 Konstantin Prass,2 Karsten Ruscher,2 Andreas Lipski,2 Rudolf Jaenisch,3 Michael A. Moskowitz,1 and Ulrich Dirnagl2

1Stroke and Neurovascular Regulation Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, 2Division of Experimental Neurology, Department of Neurology, Charite Hospital, 10098 Berlin, Germany, and 3Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142

DNA methylation is important for controlling the profile of gene expression and is catalyzed by DNA methyltransferase (MTase), an enzyme that is abundant in brain. Because significant DNA damage and alterations in gene expression develop as a consequence of cerebral ischemia, we measured MTase activity in vitro and DNA methylation in vivo after mild focal brain ischemia. After 30 min middle cerebral artery occlusion (MCAo) and reperfusion, MTase catalytic activity and the 190 kDa band on immunoblot did not change over time. However, [3H]methyl-group incorporation into DNA increased significantly in wild-type mice after reperfusion, but not in mutant mice heterozygous for a DNA methyltransferase gene deletion (Dnmt1S−/S). Dnmt1S−/+ mice were resistant to mild ischemic damage, suggesting that increased DNA methylation is associated with augmented brain injury after MCA occlusion. Consistent with this formulation, treatment with the MTase inhibitor 5-aza-2′-deoxycytidine and the deacetylation inhibitor trichostatin A conferred stroke protection in wild-type mice. In contrast to mild stroke, however, DNA methylation was not enhanced, and reduced dnmt gene expression was not protective in an ischemia model of excitotoxic/necrotic cell death. In conclusion, our results demonstrate that MTase activity contributes to poor tissue outcome after mild ischemic brain injury.

Key words: cerebral ischemia; delayed cell death; DNA damage; DNA methylation; DNA methyltransferase; gene expression

Mammalian DNA methylation is a covalent, postreplicative modification of genomic DNA and has been implicated in development and differentiation (Li et al., 1992; Panning and Jaenisch, 1998), X-chromosome inactivation (Cedar and Razin, 1990), imprinting (Li et al., 1993; Razin and Cedar, 1994; Tucker et al., 1996a,b; Surani, 1998), and cancer (Baylin et al., 1991; Counts and Goodman, 1995; Laird et al., 1995; Jones, 1996). DNA methylation is catalyzed by the maintenance DNA (cytosine-5) methyltransferase enzyme (MTase, EC 2.1.1.37) and S-adenosyl methionine (SAM) as methyl donor (Jones, 1996; Lengauer et al., 1997; Okano et al., 1998). The primary substrates for MTase are CpG dinucleotides, which represent only 1–2% of the total genome, and ~70–80% of all CpG sites are methylated in adult somatic mammalian cells (Cross and Bird, 1995). Generally, DNA methylation represses gene transcription (“gene silencing”), whereas hypomethylation is correlated with active transcription (Ehrlich and Wang, 1981; Adams and Burdon, 1982; Doerfler, 1983; Cedar, 1988; Bestor, 1990; Bird, 1992; Leonhard and Bestor, 1993; Laird and Jaenisch, 1996).

It is not known whether DNA methylation is important in ischemic brain damage, but it may be of particular interest in this context because (1) MTase activity is unexpectedly high in neurons, implying a neuron-specific function in these nonreplicating cells (Goto et al., 1993; Brooks et al., 1996). (2) Brain ischemia causes DNA damage including G-T mismatches generated by deamination of 5-methyl cytosine (5-MeC), a powerful endogenous mutagen; MTase may therefore remethylate newly incorporated cytosines after DNA repair in brain (Brooks et al., 1996; Liu et al., 1996; MacManus and Linnik, 1997; Cui et al., 1999). In addition, the formation of 8-hydroxyguanine by oxygen radical injury during ischemia/reperfusion may alter methylation of adjacent cytosines (Cerda and Weitzman, 1997). (3) DNA methylation could alter gene expression, although it has not been determined whether changes in DNA methylation develop after cerebral ischemia.

In this study we examined whether there are significant differences in MTase protein, enzyme activity, and DNA methylation after experimental brain ischemia in mice and determined whether reduced levels of MTase are associated with differences in stroke outcome in transgenic mice heterozygous for a dmut1 gene deletion (Dnmt1S−/− mice).

MATERIALS AND METHODS

Transgenic mice. Mice heterozygous for the maintenance DNA methyltransferase gene (Dnmt1S−/−) were generated as described (Li et al., 1992, 1993). Dnmt1S−/+ mice are healthy, fertile, and phenotypically normal; dmut1 null mice (Dnmt1S−−) die during embryonic development (Li et al., 1992, 1993). All experiments were performed using littermates (Dnmt1S−− and Dnmt1S−/+ in a pure 129/SVJ background).

Mouse model for focal cerebral ischemia. Animal experiments were performed according to National Institutes of Health and institutional guidelines and the policy on the use of animals in neuroscience research of the Society for Neuroscience. Mice (18–22 gm) were anesthetized with
1.5% halothane (induction) and maintained on 1.0% halothane in 70% N2O and 30% O2 by face mask. Focal cerebral ischemia was induced as described (Endres et al., 1998b). In brief, MCA occlusion was produced by a silicone-coated 8–0 monofilament into the internal carotid artery. Thirty minutes or 2 hr later, the filament was withdrawn to reperfusion the brain. To insure equivalent levels of ischemia between groups, regional cerebral blood flow (rCBF) was measured by laser Doppler flowmetry using a flexible skull probe (Huang et al., 1994; Endres et al., 1998a). In randomly selected animals the left femoral artery was cannulated for arterial blood pressure and blood gas determination (Huang et al., 1994; Endres et al., 1998a). Arterial blood samples (50 μl) were analyzed for pH, partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCO2) using a blood gas/pH analyzer (Corning 178, Ciba-Corning Diagnostics, Medford, MA). Core temperature was maintained at −37 ± 0.5°C with a thermometer (FHC, Brunswick, ME) and a heating lamp during the monitoring period until 1 hr after reperfusion.

Western blotting. MTase protein levels were determined by immunoblotting of extracts of olfactory bulb, striatum, and hippocampus in Dnmt<sup>S</sup>/<sup>S</sup> and Dnmt<sup>+/−</sup> mice. To examine for time-dependent changes in MTase protein, 129/ScSn/F1 wild-type mice (Taconic Farms, Germantown, NY) underwent 30 min MCAo as above followed by reperfusion (1–72 hr) (Endres et al., 1998b). After mice were killed, brains were immediately removed, the olfactory bulbs, cortex, striatum, and hippocampus were dissected (Endres et al., 1998a). Arterial blood samples (50 μl) were analyzed for pH, partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCO2) using a blood gas/pH analyzer (Corning 178, Ciba-Corning Diagnostics, Medford, MA). Core temperature was maintained at −37 ± 0.5°C with a thermometer (FHC, Brunswick, ME) and a heating lamp during the monitoring period until 1 hr after reperfusion.

RESULTS

Effects of ischemia on MTase catalytic activity

We determined MTase catalytic activity ex vivo using an established model of 30 min MCAo followed by reperfusion (Endres et al., 1998b). As displayed in Figure 1A, cortical and striatal levels in ischemic tissue did not differ from baseline (sham) and contralateral tissues, nor did they change with time (1, 3, 6, 18 hr) during reperfusion. Levels in Dnmt<sup>S</sup>/<sup>S</sup> mice were ~50% compared with Dnmt<sup>+/−</sup> mice and also did not change over time (1, 3, 6, 18 hr) (Fig. 1B). Activity levels in cerebellum were considerably higher than in other brain regions, which agrees with the literature (Brooks et al., 1996). Hence, MTase, an enzyme with a short protein half life (Szyl, 1994), remains functionally intact after ischemia/reperfusion.

Effects of ischemia on MTase protein levels

MTase protein was measured semiquantitatively using immunoblot analysis of brain lysates probed with rabbit antisera (Tucker et al., 1996a). A band corresponding to molecular weight 190 kDa was detected on immunoblot. MTase protein levels were ~50% in Dnmt<sup>S</sup>/<sup>S</sup> mice compared with the wild-type strain in olfactory bulb (OB), striatum (STR), and hippocampus (HIP) (Fig. 2A). To characterize the fate of MTase after brain ischemia, we measured MTase protein after 30 min MCAo/reperfusion. No differences were found over time in ischemic striatum after reperfusion of 0, 1, 3, 6, 12, 18, 24, 48, and 72 hr (Fig. 2B). Hence, MTase levels did not change over time after ischemia/reperfusion.

Effects of cerebral ischemia on DNA methylation in vivo

To measure newly incorporated methyl groups into DNA during brain ischemia/reperfusion in vivo, animals were first subjected to 30 min MCAo, and on reperfusion a labeled methyl-group precursor of SAM (L-[methyl-<sup>3H</sup>]methionine) was administered. Twelve hours after reperfusion, DNA methylation was significantly higher in ischemic striatum (4.1-fold) and cortex (3.2-fold) compared with the respective contralateral tissues in wild-type mice (Dnmt<sup>+/−</sup> littermates) (Fig. 3A). DNA methylation, how-
the ischemic striatum, the density of viable cells was 2.4-fold higher in controls (Fig. 4). In fact, lesion size was significantly (29%) reduced compared with quantitated lesion volume after 30 min MCAo/72 hr reperfusion. MTase activity was measured in ischemic cortex (COR) and striatum (STR) along with the respective contralateral tissue and sham (S)-operated animals. MTase activity was measured in nuclear extracts in vitro using a hemimethylated oligo-probe. Levels in cerebellum (CER) are shown for comparison. n = 2 animals per time point. Mean ± SE. p > 0.05.

ever, did not increase in ischemic tissue of DnmtS/+ mice (Fig. 3B). Together, these results demonstrate that methyl group incorporation increases after ischemia/reperfusion in wild-type but not in DnmtS/+ mice.

Smaller cerebral lesions and improved neuronal survival in DnmtS/+ mice after mild stroke

To determine whether the failure to increase DNA methylation altered the susceptibility of DnmtS/+ mice to tissue injury, we quantitated lesion volume after 30 min MCAO/72 hr reperfusion. In fact, lesion size was significantly (29%) reduced compared with controls (Fig. 4A). Moreover, when neurons were counted within ischemic striatum, the density of viable cells was 2.4-fold higher in the DnmtS/+ mice compared with controls (Fig. 4B). These results demonstrate that reduced MTase activity is beneficial during mild cerebral ischemia.

Systemic physiological parameters are unaltered in DnmtS/+ mice

Because alterations in systemic and cerebrovascular parameters can modify outcome after stroke, we excluded possible effects of such variables by careful physiological monitoring. Rectal temperature, arterial blood pressure, pH, partial pressure of oxygen and carbon dioxide before, during, and after ischemia did not differ between groups (Table 1). TCBF, measured with a laser Doppler flow probe, decreased to <20% of baseline ischemia in all animals and returned to ~100% within 5 min after reperfusion (Table 1). Blood pressure after reperfusion was somewhat lower in DnmtS/+ mice compared with controls (82 ± 6 vs 101 ± 5 mmHg) (Table 1). Differences in blood pressure after ischemia between groups could possibly be explained by specific gene expression changes (e.g., of endothelial NO synthase); however, they are unlikely to explain improved outcome in DnmtS/+ mice because systemic hypotension normally aggravates ischemic damage (Harms et al., 2000).

Pharmacological inhibition of DNA methylation and histone deacetylation confers stroke protection in wild-type mice

To test the theory that a pharmacological inhibitor of MTase confers stroke protection in wild-type mice, we treated 129/SV mice with the MTase inhibitor 5-aza-dC. Twenty micrograms given intracerebroventricularly 10 min before 30 min MCAO reduced lesion volume by 34% at 72 hr (Fig. 5). After a slightly different ischemia protocol (45 min MCAO followed by 48 hr reperfusion), lesion size was 54% smaller in the 5-aza-dC-treated animals (43.2 ± 12.6 vs 19.9 ± 0.8 mm^3 in control vs treated mice, respectively; p < 0.001; n = 4 per group). We also determined methyl group incorporation into DNA (12 hr reperfusion) in 5-aza-dC-treated animals versus vehicle-injected animals. For this experiment, 400 μl [methyl-3H]methionine without additional PBS was used. A 2.72-fold increase compared with the contralateral side was found in the ischemic territory of vehicle-injected animals (90 ± 14 vs 244 ± 75 dpm in contralateral vs

Figure 2. A, MTase protein levels in olfactory bulb (OB), striatum (STR), and hippocampus (HIP) in brain lysates from normal (wt) and DnmtS/+ mice (s/+). Brain lysates were subjected to SDS-PAGE and immunoblot analysis performed using a polyclonal MTase antibody. The experiment was repeated three times; a representative experiment is shown. B, Time-dependent changes in MTase protein expression in striatum during reperfusion after 30 min middle cerebral artery occlusion. MTase protein was present in normal brain (sham) and did not change over time (0, 1, 3, 6, 12, 18, 24, 48, and 72 hr) between left (L = ischemic) and right (R = non-ischemic) hemispheres. The experiment was repeated three to four times per time point; a representative experiment for the time points 3, 6, and 18 hr is shown.
ischemic tissue, respectively; 3 μg DNA; n = 4). However, in 5-aza-dC-treated animals this increase was only 1.38-fold (101 ± 13 vs 140 ± 31 dpm in contralateral vs ischemic tissue, respectively; 3 μg DNA; n = 3).

Because deletion/inhibition of MTase may augment the level of gene transcription, we tested whether increasing gene transcription by a related yet distinct mechanism (i.e., inhibition of histone deacetylase) would also protect from ischemic brain injury. Accordingly, when animals were pretreated with TSA, a highly specific inhibitor of histone deacetylase (Yoshida et al., 1995) (0.2 or 2 μg, i.c.v., given 10 min before ischemia), lesion size was significantly reduced after 30 min of filamentous middle cerebral artery occlusion (Fig. 5). After 45 min MCAo/48 hr reperfusion, lesion size was 48% smaller in TSA-treated animals (43.2 ± 12.6 vs 22.4 ± 1.2 mm³ in control vs 2 μg TSA, respectively; p < 0.001; n = 4 per group).

Table 1. Physiological variables at baseline and during ischemia in DnmtS/+ and DnmtS/+ mice

<table>
<thead>
<tr>
<th>Parameter</th>
<th>DnmtS/+ mice</th>
<th>DnmtS/+ mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>MABP (mmHg)</td>
<td>89 ± 3</td>
<td>87 ± 4</td>
</tr>
<tr>
<td>Baseline</td>
<td>91 ± 5</td>
<td>88 ± 6</td>
</tr>
<tr>
<td>After</td>
<td>101 ± 5</td>
<td>82 ± 6*</td>
</tr>
<tr>
<td>pH</td>
<td>7.32 ± 0.01</td>
<td>7.29 ± 0.02</td>
</tr>
<tr>
<td>Baseline</td>
<td>7.35 ± 0.01</td>
<td>7.33 ± 0.02</td>
</tr>
<tr>
<td>PaO₂ (mmHg)</td>
<td>164 ± 10</td>
<td>132 ± 21</td>
</tr>
<tr>
<td>Baseline</td>
<td>130 ± 13</td>
<td>123 ± 20</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td>43 ± 2</td>
<td>46 ± 3</td>
</tr>
<tr>
<td>Baseline</td>
<td>38 ± 1</td>
<td>43 ± 3</td>
</tr>
<tr>
<td>rCBF (%)</td>
<td>100 ± 0</td>
<td>100 ± 0</td>
</tr>
<tr>
<td>Before</td>
<td>14 ± 5</td>
<td>11 ± 3</td>
</tr>
<tr>
<td>During</td>
<td>103 ± 8</td>
<td>100 ± 7</td>
</tr>
<tr>
<td>Weight (gm)</td>
<td>21.1 ± 1.0</td>
<td>19.7 ± 0.9</td>
</tr>
<tr>
<td>CT (°C)</td>
<td>37.1 ± 0.1</td>
<td>37.1 ± 0.1</td>
</tr>
</tbody>
</table>

Animals were subjected to 30 min filamentous middle cerebral artery occlusion followed by reperfusion (Endres et al., 1998b). MABP (mean arterial blood pressure) and rCBF (regional cerebral blood flow) were measured at baseline, during ischemia, and after 30 min reperfusion (Huang et al., 1994). Fifty microliters of blood were withdrawn twice, before ischemia and directly after reperfusion for blood gas determination (pH, PaO₂, PaCO₂). Animals were weighed before the onset of the experiment (body weight in grams). Core temperature (CT) was controlled and recorded by means of a feedback temperature control unit. *p < 0.05 vs control; otherwise there were no statistically significant differences between groups. n = 5 per group. Mean and SE, ANOVA, and Scheffe’s test.

Figure 4. A. Infarct volume was 29% smaller in DnmtS/+ mice compared with DnmtS/+ mice after 30 min filamentous middle cerebral artery occlusion (MCAo) and 72 hr reperfusion. Brain lesion volume was determined on serial coronal hematoxylin and eosin-stained cryostat sections (20 μm). B. DnmtS/+ mice had significantly higher numbers of viable cells in ischemic striatum after 30 min MCAo/72 hr reperfusion compared with controls. Viable cells with neuronal appearance were counted on coronal sections (20 μm) through the anterior commissure. Mean ± SE, n = 14 and 15 animals per group. *p < 0.05 compared with DnmtS/+ mice. Student’s t test.

Figure 5. Treatment with the MTase inhibitor 5-aza-2'-deoxycitidine (5-aza-dC; 20 μg) or the specific deacetylination inhibitor trichostatin A (TSA; 1 or 10 μg) reduced lesion size after 30 min of filamentous middle cerebral artery occlusion and 72 hr of reperfusion compared with vehicle in 129/SV mice. Drugs or vehicle was administered intracerebroventricuarily 10 min before ischemia. Lesion volume was determined quantitatively. Data are presented as mean ± SE, n = 5–9 animals per group. *p < 0.01 versus vehicle. Student’s t test.
For both the 5-aza-dC and the TSA experiments, we observed no significant differences in physiological parameters between groups (CBF, blood pressure, blood gases, rectal temperatures) that could influence ischemia outcome (n = 5 animals per group; ANOVA plus Scheffe’s test; data not shown).

**Damage after severe stroke is not blunted in Dnmt"S/" mice.**

Excitotoxic and free radical-mediated mechanisms predominate after prolonged periods of ischemia presumably because of necrotic mechanisms of cell death, whereas apoptotic mechanisms are unmasked in milder forms of ischemia (Choi, 1988; Endres et al., 1997, 1998b). We therefore tested the effects of dnmt1 heterozygosity in a model of severe stroke (2 hr MCAo and reperfusion).

First, we determined whether DNA methylation increases after more prolonged ischemia as it does after mild ischemia (30 min MCAo). Methyl group incorporation was not increased after 2 hr MCAo in wild-type mice (Fig. 6A). Moreover, there was no difference in infarct size between Dnmt"S/+" mice and wild-type littermates after 2 hr MCAo and 22 hr reperfusion and infarct volume was quantitated, no difference in indirect infarct volume was noted between groups. This result was confirmed by a direct method to measure infarct volume (137 ± 19.6 vs 121.7 ± 11.5 mm³ for Dnmt"S/+" vs Dnmt"S/+" mice, respectively). Mean ± SE. *p < 0.05. Paired Student’s t test. B. When Dnmt"S/+" and Dnmt"S/" mice were subjected to 2 hr MCAo/24 hr reperfusion and infarct volume was quantitated, no difference in indirect infarct volume was noted between groups. This result was confirmed by a direct method to measure infarct volume (137 ± 19.6 vs 121.7 ± 11.5 mm³ for Dnmt"S/+" vs Dnmt"S/+" mice, respectively). Mean ± SE. n = 4 and 5, p > 0.05 compared with wild type. Student’s t test.

**DISCUSSION**

This is the first report to implicate DNA methylation in the evolution of ischemic brain injury. Ischemia/reperfusion generated a three- to fourfold increase in methyl group incorporation in brain, whereas this increase was not observed in transgenic animals expressing reduced MTase levels; furthermore, the mutant brain was resistant to injury as evidenced by decreased striatal damage and increased numbers of surviving striatal neurons. There were no group differences in genetic background or differences in physiological or cerebrovascular parameters to explain these results. Together, this may mean that DNA methylation may render the tissue more vulnerable to ischemic injury and may increase as a consequence of such injury. The former postulation is supported by the finding that ischemic brain injury can be reduced by treatment with an inhibitor of DNA methylation, 5-aza-dC.

**DNA methylation after cerebral ischemia**

An *in vivo* methylation assay was developed to measure newly incorporated methyl groups into DNA using 1-[methyl-"H]methylamine as methyl donor. ["H]methyl groups became incorporated into DNA, and we expect that most of the incorporated methyl groups was added to cytosine residues, although thymine methylation is a theoretical possibility (Razin et al., 1970). Although there were significant differences in DNA methylation *in vivo* between Dnmt"S/+" and Dnmt"S/" mice after ischemia, baseline methylation (contralateral hemisphere and cerebellum) did not differ, which agrees with previous findings in Dnmt"S/+" cells (Li et al., 1992, 1993; Laird and Jaenisch, 1996). Absolute numbers for methylation frequency could not be obtained with our assay (assuming that the endogenous SAM pool was completely replaced by [methyl-"H]SAM and that ["H]methyl groups were incorporated only into CpG dinucleotides, we estimate the striatal methylation frequency as 4.5 × 10⁶ (control) vs 12.2 × 10⁶ (ischemia) per CpG dinucleotide). Despite significant increases in methyl group incorporation into DNA, protein amount and enzymatic activity of MTase were unchanged after cerebral ischemia and reperfusion, although small differences may have been missed because of assay sensitivity. Possible explanations include induction of other MTases, which seems unlikely however, in view of the results in Dnmt"S/+" mice. A more reasonable explanation is an increase in MTase substrate, i.e., hemimethylated DNA, the mechanisms of which are discussed below.

Ischemia-induced methylation may reflect MTase activity in neurons after DNA damage and repair. Ischemic stress facilitates deamination of 5′MeC leading to G-T mismatches. For example, after forebrain ischemia, the mutation spectrum indicates that 58% of mutants with base substitutions (or one-third of all mutations) involved G-T mismatches (Liu et al., 1996). MTase may remethylate cytosine residues after base-excision repair of mismatches (Brooks et al., 1996; Brooks, 1998). Cui et al. (1999) reported specific DNA damage 15 min after focal ischemia (i.e., in the c-fos gene), most of which was effectively repaired 60 min after ischemia by base-excision repair. Another important mechanism in this respect is the observation that the formation of oxygen radicals [i.e., 8-hydroxyguanine (oh8dG)] profoundly alters methylation of adjacent cytosines, suggesting a role for oxidative injury in the formation of aberrant DNA methylation patterns (Cerda and Weitzman, 1997). Interestingly, oh8dG levels increased fourfold after forebrain ischemia (Liu et al., 1996), and we observed a 2.7- to 4.1-fold increase of methylation in a focal model. However, it is unlikely that this mechanism can solely explain methylation changes in our model. Moreover, the recent discovery of a DNA demethylase (Bhattacharya et al., 1999) and the notion that DNA methylation may be a reversible biological phenomenon (Rachmandani et al., 1999) shed new light on DNA methylation in postmitotic cells such as neurons. Notably, our preliminary results indicate that ischemic resistance was also enhanced in genetically engineered mice in which the dnmt1
gene was selectively deleted in neurons (M. Endres, G. Fan, and R. Jaenisch, unpublished observation). Alternatively, increased DNA methylation after brain ischemia could relate to mitotic activity and DNA replication in non-neuronal cells such as glia or progenitor cells (Lee et al., 1996).

In addition, administration of 5-aza-dC, an inhibitor of MTase, was able to significantly inhibit DNA methylation when administered intracerebroventricularly before ischemia. Notably, 5-aza-dC, which is known to easily penetrate cells (Chabor, et al., 1983), requires incorporation into DNA to inhibit MTase (Laird et al., 1995). In accordance with the above discussed mechanisms for DNA methylation in the adult ischemic brain, 5-aza-dC could be incorporated into DNA of replicating non-neuronal cells or newly repaired DNA of neurons (Brooks et al., 1996; Liu et al., 1996; Brooks, 1998; Cui et al., 1999).

Possible neuroprotective mechanisms

In our study we showed that suppression of DNA methylation conferred resistance to ischemia as well as specific inhibition of histone deacetylation. An inhibitor of DNA methylation, 5-aza-dC, caused significant reduction in ischemic injury as did a deficiency in Dnmt1 gene expression. In addition to methylation, histone deacetylation has also been linked to gene silencing and provides a second global mechanism by which genes are regulated (Yoshida et al., 1995; Eden et al., 1998; Jones et al., 1998; Nan et al., 1998). In fact, the two mechanisms have themselves been linked recently by data showing that transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex (Eden et al., 1998; Jones et al., 1998; Nan et al., 1998). We infer from our data that DNA methylation and histone deacetylation alter gene expression after ischemia in such a way as to render tissue susceptible to injury. According to a "good versus bad gene" theory, this could relate to overexpression of protective/antiapoptotic genes (e.g., c-fos, bel-2, sod) or repression of deleterious/proapoptotic genes (e.g., bad, bax). Cui et al. (1999) recently reported specific alterations in gene expression of c-fos after focal ischemia/reperfusion. Hence, neuroprotection may relate not only to the specific characteristics of delayed neuronal cell death after mild stroke but to ischemia-induced changes in gene expression mediated by DNA methylation and histone deacetylation. To further differentiate between possible necrotic and apoptotic mechanisms, we used two different models of cerebral ischemia (30 min vs 2 hr MCAo) (Endres et al., 1998b). The fact that methyl group incorporation did not increase after 2 hr MCAo and mutants partially deficient in MTase were not protected from severe stroke points to fundamental differences in the pathways of mild versus severe ischemic injury.

Experiments using Dnmt1−/− mice cannot distinguish between effects of Dnmt1 heterozygosity during development versus effects in the adult brain. However, the fact that methylation patterns are similar between Dnmt1−/− and Dnmt1+/− cells (Li et al., 1992, 1993; Laird and Jaenisch, 1996) and that inhibiting MTase activity with 5-aza-dC was neuroprotective during ischemia suggests that effects in adult brain are responsible for protection. Experiments using conditional knockouts will help to resolve this issue.

In addition to the above epigenetic mechanisms, the enzyme MTase could enhance DNA maturation. Under certain conditions, especially during SAM deficiency, C-T and C-U transitions can be facilitated by MTase directly (Wyszynski et al., 1994; Gonzalez and Jones, 1997). Possibly, the mutagenic potency of MTase is compensated for by an effective DNA repair mechanism. This would imply a protective role for mismatch repair versus deleterious effects of MTase and DNA methylation. Therefore, although this mechanism has yet to be convincingly demonstrated in mammals, a direct genetic mechanism by which MTase contributes to ischemic damage is possible. Notably, SAM administration is neuroprotective in models of cerebral ischemia in rats and gerbils (Sato et al., 1988; Rao et al., 1997). It will be interesting to measure SAM levels after cerebral ischemia and conditions of MTase deficiency in our model.

In conclusion, we demonstrate that DNA methylation increases in vivo after ischemia/reperfusion and that reduced levels of MTase in brain protect from ischemic injury. These observations underscore the potential importance of DNA methylation to mechanisms of injury and repair in the postischemic brain.

REFERENCES


